CARDIOVASCULAR AND RENAL OUTCOMES WITH CANAGLIFLOZIN IN PEOPLE WITH TYPE 2 DIABETES ACCORDING TO BASELINE USE OF METFORMIN
AACE ePoster Library. Neuen B. 04/27/19; 262729; 597533
Brendon Neuen
REGULAR CONTENT
Login now to access Regular content available to all registered users.
Rate & Comment (0)
{{ help_message }}
{{filter}}